QCG
ABBV icon

Quadrant Capital Group’s AbbVie ABBV Stock Holding History

Quadrant Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2M Buy
56,226
+2,339
+4% +$519K 0.37% 34
2025
Q4 		$12.3M Sell
53,887
-460
-0.8% -$105K 0.37% 33
2025
Q3 		$12.6M Buy
54,347
+1,639
+3% +$334K 0.41% 32
2025
Q2 		$9.78M Sell
52,708
-522
-1% -$97K 0.35% 38
2025
Q1 		$11.2M Buy
53,230
+18,701
+54% +$3.64M 0.41% 28
2024
Q4 		$6.14M Sell
34,529
-584
-2% -$107K 0.42% 29
2024
Q3 		$6.93M Sell
35,113
-251
-0.7% -$46.8K 0.48% 27
2024
Q2 		$6.07M Buy
35,364
+823
+2% +$136K 0.45% 28
2024
Q1 		$6.29M Buy
34,541
+1,233
+4% +$212K 0.5% 27
2023
Q4 		$5.16M Buy
33,308
+3,537
+12% +$516K 0.44% 31
2023
Q3 		$4.44M Buy
29,771
+1,892
+7% +$278K 0.44% 33
2023
Q2 		$3.76M Sell
27,879
-856
-3% -$126K 0.37% 39
2023
Q1 		$4.58M Buy
28,735
+1,811
+7% +$277K 0.48% 30
2022
Q4 		$4.35M Buy
26,924
+2,047
+8% +$314K 0.49% 31
2022
Q3 		$3.34M Buy
24,877
+2,733
+12% +$392K 0.44% 31
2022
Q2 		$3.39M Sell
22,144
-66
-0.3% -$10.1K 0.46% 35
2022
Q1 		$3.6M Buy
22,210
+935
+4% +$136K 0.44% 38
2021
Q4 		$2.88M Buy
21,275
+6,986
+49% +$825K 0.34% 47
2021
Q3 		$1.54M Buy
14,289
+171
+1% +$19.5K 0.22% 75
2021
Q2 		$1.59M Buy
14,118
+460
+3% +$51.8K 0.23% 70
2021
Q1 		$1.48M Buy
13,658
+599
+5% +$64.1K 0.24% 65
2020
Q4 		$1.4M Sell
13,059
-37
-0.3% -$3.56K 0.26% 63
2020
Q3 		$1.15M Sell
13,096
-1,938
-13% -$182K 0.25% 66
2020
Q2 		$1.48M Sell
15,034
-3,590
-19% -$316K 0.33% 55
2020
Q1 		$1.41M Buy
18,624
+609
+3% +$51.9K 0.24% 79
2019
Q4 		$1.55M Buy
18,015
+2,749
+18% +$228K 0.19% 89
2019
Q3 		$1.14M Buy
15,266
+1,349
+10% +$92.5K 0.17% 93
2019
Q2 		$990K Buy
13,917
+844
+6% +$66.3K 0.16% 102
2019
Q1 		$1.03M Buy
13,073
+2,793
+27% +$228K 0.18% 89
2018
Q4 		$928K Sell
10,280
-982
-9% -$86.4K 0.25% 75
2018
Q3 		$1.04M Sell
11,262
-92
-0.8% -$8.72K 0.3% 59
2018
Q2 		$1.03M Buy
11,354
+74
+0.7% +$7.23K 0.36% 59
2018
Q1 		$1.05M Buy
11,280
+92
+0.8% +$10.1K 0.38% 57
2017
Q4 		$1.06M Buy
11,188
+58
+0.5% +$5.47K 0.42% 50
2017
Q3 		$970K Buy
11,130
+24
+0.2% +$1.83K 0.4% 56
2017
Q2 		$726K Buy
11,106
+1,051
+10% +$70.7K 0.32% 64
2017
Q1 		$643K Buy
10,055
+462
+5% +$29K 0.28% 71
2016
Q4 		$589K Buy
9,593
+219
+2% +$13.4K 0.3% 64
2016
Q3 		$580K Buy
9,374
+40
+0.4% +$2.59K 0.38% 46
2016
Q2 		$566K Buy
9,334
+36
+0.4% +$2.19K 0.39% 49
2016
Q1 		$523K Buy
9,298
+675
+8% +$37.6K 0.34% 54
2015
Q4 		$503K Sell
8,623
-623
-7% -$35.9K 0.35% 61
2015
Q3 		$497K Sell
9,246
-708
-7% -$46.1K 0.34% 55
2015
Q2 		$665K Buy
+9,954
New +$650K 0.42% 42

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrant Capital Group's ABBV Position: Q1 2026 in Review

Quadrant Capital Group increased its AbbVie (ABBV) stake by 4.3% in Q1 2026, buying an estimated $519K and bringing the position to 56,226 shares worth $12.2M. The position accounts for 0.37% of the portfolio, ranked #34.

Quadrant Capital Group first reported a position in ABBV in Q2 2015 and has held it in 44 quarters since. The position peaked at $12.6M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Quadrant Capital Group held 56,226 shares of AbbVie worth $12.2M as of Q1 2026.
  • Quadrant Capital Group bought 2,339 AbbVie shares in Q1 2026, an estimated $519K.
  • AbbVie made up 0.37% of Quadrant Capital Group's portfolio in Q1 2026, its #34 holding.
  • Quadrant Capital Group first reported a position in AbbVie in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's AbbVie position peaked at $12.6M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.